#United States #Chicago #Insmed #Brinsupri #CHEST 2025

Insmed to Unveil Phase 3 ASPEN Study Results at CHEST 2025

Insmed Incorporated, a leading biopharmaceutical company, is gearing up to present groundbreaking results from its Phase 3 ASPEN study at the upcoming CHEST 2025 conference. This event, hosted by the American College of Chest Physicians, will take place from October 19 to October 22 in Chicago, Illinois. The focus of the presentations will be the efficacy and safety of BRINSUPRI™ (brensocatib), a novel therapy designed to treat patients with non-cystic fibrosis bronchiectasis (NCFB).

Exciting Highlights

During the conference, Insmed plans to showcase six abstracts derived from the ASPEN study, which centers around impactful insights on how brensocatib influences the treatment of NCFB. Notably, one of the significant aspects to be highlighted includes late-breaking data regarding structural lung changes as evaluated through a high-resolution CT substudy. Further analyses will delve into areas such as the suppression of neutrophil serine proteases (NSPs) and symptom reduction outcomes among patients experiencing this chronic lung condition.

Dr. Martina Flammer, Chief Medical Officer at Insmed, expressed the enthusiasm surrounding the event: "We are thrilled to have a strong presence at CHEST, the first major U.S. respiratory congress since the FDA approval of BRINSUPRI. This milestone offers an exciting opportunity to engage with the respiratory community and highlight the breadth of our research."

Detailed Presentations

The schedule for the event includes several prominent presentations:

• - Oral Presentation: Patrick Flume will discuss the differences in symptom burden between patients treated with brensocatib and those receiving placebo, utilizing post-hoc data from the ASPEN trial.
• - Late-Breaking Abstract Poster Session: James Chalmers will present findings on the impact of brensocatib on CT outcomes in patients with NCFB.
• - Poster Session: A range of topics will be covered, including:

- Colin Swenson on the efficacy and safety of brensocatib in patients with comorbid chronic obstructive pulmonary disease (COPD).
- Doreen Addrizzo-Harris on the outcomes for Asian patients with NCFB.
- Charles L. Daley discussing effects on neutrophil serine protease levels.
- Carlos Fernandez examining changes in symptom burden during exacerbations among those treated with placebo.

These presentations are set to provide in-depth explorations of brensocatib's mechanism of action and its potential role in the management of bronchiectasis and related pulmonary conditions.

Addressing Patient Needs

Bronchiectasis is characterized by the permanent dilation of bronchi due to cycles of infection and inflammation, often leading to significant morbidity in patients. There is a high demand for therapies that specifically address this condition, particularly since most cases seen in adults are non-cystic fibrosis related. Current estimates suggest that in the United States alone, approximately 500,000 individuals suffer from NCFB, highlighting the urgent need for effective treatment options.

Insmed’s Commitment to Innovation

Insmed remains steadfast in its mission to redefine the treatment landscape for serious diseases through innovative therapies like BRINSUPRI. The company emphasizes its dedication to addressing the unmet needs of patient populations affected by debilitating conditions.

In summary, the insights shared at CHEST 2025 will not only underscore the therapeutic potential of brensocatib but also affirm Insmed's role as a forerunner in respiratory health innovation. As this annual meeting unfolds, stakeholders in healthcare look forward to significant advancements in understanding and managing non-cystic fibrosis bronchiectasis effectively.